Heart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF

Similar documents
Heart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for

Inverclyde CHP Protected Learning Event- Heart Failure

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

Frimley Health Area Prescribing Committee

HEART FAILURE SUMMARY. and is associated with significant morbidity and mortality. the cornerstone of heart failure treatment.

1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare?

Guideline-Directed Medical Therapy

Heart Failure Clinician Guide JANUARY 2016

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

Heart Failure from a GP perspective

Heart Failure Clinician Guide JANUARY 2018

A patient with decompensated HF

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

New NICE Heart Failure Guidelines What do they mean for primary and secondary care, and patients?

NHS GG&C -Mental Health Services. Lithium Ward Bundle

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF CHRONIC HEART FAILURE with left ventricular systolic dysfunction

Guidelines for the Prescribing of Sacubitril / Valsartan

Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic

STANDARD treatment algorithm mmHg

LXIV: DRUGS: 4. RAS BLOCKADE

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%

NHS GRAMPIAN MEDICAL TREATMENT GUIDELINES FOR CHRONIC HEART FAILURE (CHF) DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Enhancing the Quality of Heart Failure Care

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Enhancing the Quality of Heart Failure Care

Heart Failure Nurse Specialist: Pharmacological Management of Heart Failure

Objectives. Outline 4/3/2014

NHS QIS National Measurement of Audit Acute Coronary Syndrome

Factsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

Management of Hypertension

An Overview of the Management of Congestive Heart Failure in Malta

Combination of renin-angiotensinaldosterone. how to choose?

À ². The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 September 2012

North of Tyne and Gateshead Guidelines for Management and Diagnosis of Hypertension Reviewed August 2017

Ivabradine for treating chronic heart failure: NICE technology appraisal guidance 267 Information for East Kent GPs revised July 2015

SECONDARY CARE HEART FAILURE SERVICE GUIDELINES (2011)

MANAGEMENT OF HEART FAILURE with Reduced Ejection Fraction (HFREF)

Your medicines for heart failure

*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.

The Failing Heart in Primary Care

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists

Shared Care Guideline Metolazone for fluid management in CKD (Adults)

Chronic heart failure

NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing

Sandwell Community Heart Failure Team. Community Heart failure Specialist Nurses: Hilda O Keeffe- Henry and Jacqui Elson-Whittaker

*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration

CLINICAL PRACTICE GUIDELINE

Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE

Cardiology. Presented by: Dr Paul Bethell GP Lead for Planned Care

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute

CORLANOR (ivabradine) oral tablet

Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography

Heart Failure. GP Update Refresher 18 th January 2018

Summary/Key Points Introduction

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017

Clinical guideline Published: 25 August 2010 nice.org.uk/guidance/cg108

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

ACE. Inhibitors. Quiz feedback

Heart Failure: Guideline-Directed Management and Therapy

NICE Chronic Heart Failure Guidelines in Adults 2018

Profile number: 3 MSc Clinical Pharmacy / Clinical and Health Services Pharmacy. Patient Profile

Clinical guideline for the introduction of Sacubitril Valsartan in primary and secondary care in Cornwall

REVIEW OF HEART FAILURE INDICATORS IN CHESHIRE AND MERSEYSIDE

HEART FAILURE: PHARMACOTHERAPY UPDATE

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Nurse Prescribing in Cardiology. Jan Keenan Consultant Nurse; NMP Lead

5.2 Key priorities for implementation

Chronic heart failure

1. Introduction. Abstract

Suspected Heart Failure (inc LVSD)

A New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG

The Atrial Fibrillation Clinic in Llanelli. Dr Lena Marie Izzat Consultant Cardiovascular Physician

COMPASS Therapeutic Notes on the Pharmacological Management of Heart Failure in Primary Care

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

Antialdosterone treatment in heart failure

Translating Evidence into Practice A Workshop on Heart Failure

Heart Failure in 2012 with reference to NICE Guidance Dr Maurice Pye Consultant Cardiologist York District Hospital

Specialist Palliative Care Audit and Guidelines Group (SPAGG)

1. Confirmation of Diagnosis

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

Heart Failure Management Policy and Procedure Phase 1

Heart Failure. Dr. William Vosik. January, 2012

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Heart Failure. Dr. Alia Shatanawi

The Patient Journey through Heart Failure Primary Care Handout

2016 Update to Heart Failure Clinical Practice Guidelines

Transcription:

Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange chest x-ray Consider alternative diagnosis Refer to the Heart Failure Clinic at VHK for Echo and expert assessment Refer via SCI Gateway Victoria Hospital HF Clinic (Please use the specific HF clinic slot) Diagnosis confirmed by Echo Multidisciplinary management plan agreed with patient Transfer back into primary care with appropriate specialist follow up as required Ensure patient is included on the HF register and is coded as having a diagnosis of HF confirmed by echo or specialist assessment: (QOF HF2)

Known HF presenting with worsening symptoms Acute Rapid deterioration in clinical condition Chronic Deterioration over days or weeks Does patient have signs of fluid overload? Admit to Cardiology NO YES Rapid expert assessment required Optimise diuretic Consider spironolactone if not prescribed (Appendix 1) Initiate treatment to ensure patient s symptoms are being managed prior to being seen in HF clinic Refer to the Heart Failure Clinic at VHK for review and management (Patient will be seen at next HF clinic maximum time to appointment 6 days). Refer via SCI Gateway Victoria Hospital HF Clinic (Please use the specific HF clinic slot) If a more urgent review is required please email Fife.uhb.heartfailureservice@nhs.net Patients referred via this route will be seen at a cardiology clinic the following day. Weekly visits to HF clinic until patient stabilizes Multidisciplinary management plan agreed by patient (Appendix 3) If supportive palliative care is required ensure patient is on the non cancer palliative care register

HF Management after diagnosis or discharge from hospital Is patient on maximum tolerated evidence based treatment? Yes Multidisciplinary management plan agreed by patient supported by the Heart Failure Liaison Nurse Service (Appendix 3) No Complete optimisation of medical therapy as set out in appendix 2 Multidisciplinary management plan agreed by patient with support of the Heart Failure Liaison Nurse Service (Appendix 3) The Heart Failure Liaison Service is based at: Address: Administration Building, Cameron Hospital, Windygates. Tel No: 01592-226884 Fax: 01592-226989 Email: Fife-uhb.heartfailureservice@nhs.net The Specialist Nurses are available for support and advice and can be contacted by patients, their GPs and carers.

Spironolactone Flow Chart Indications Should be considered for patients NYHA III-IV who have been optimised on an ACE-I or ARB and a beta -blocker and continue to be symptomatic Contra-indications Patient is treated with both an ACE-I and an ARB Significant hyperkalaemia >5mmol/l Significant renal dysfunction Cr >220mmol/l Pre-initiation checks Where appropriate, stop potassium supplements & other potassium sparing diuretics 2 weeks before starting spironolactone. Substitute with a loop diuretic e.g. furosemide. Check blood chemistry: Creatinine <220umol/l Urea < 12mmol/l Potassium <4.5mmol/l Commence Spironolactone Initial dose Increments Target 25mg od double to 50mg od (Where dose reduction may be required consider 25mg od then 25mg alternate days depending on biochemistry) Monitoring Blood chemistry should be checked initially and at weeks 1, 2 & 4 Then 4 weekly for 3 months 3 monthly for 1 year Then 6 monthly thereafter Stop spironolactone and seek specialist advice where The patient develops: Diarrhoea Vomiting Or any other cause of sodium & water depletion Gynaecomastia Consider eplerenone as an alternative. Initiate on 25mg daily, and increase to 50mg within four weeks taking into consideration serum potassium levels. Monitor as above (Where dose reduction may be required consider 25mg od then 25mg on alternate days depending on serum potassium levels) Blood chemistry Urea >18mmol/l (or by 50% from baseline) Creatinine 250umol/l (or by 25% from baseline) Potassium > 5.5mmol/l

Appendix 2 HEART FAILURE TITRATION GUIDANCE CONDITION Base line treatment Fluid overload NYHA class III or IV Atrial fibrillation EVIDENCE BASED DRUGS ACE-I ARB (if intolerant of ACE-I) Betablocker Loop diuretic Aldosterone antagonist Warfarin YES NO MTD* OD** DOCUMENT CONTRAINDICATION *Maximum tolerated dose **Optimal dose ACE INHIBITOR (ACE-I) Name of drug Start dose Target Ramipril 2.5mg od 10mg od Perindopril 2mg od 4mg od Trandolapril 1mg od 4mg od ANGIOTENSIN RECEPTOR BLOCKER (ARB) Name of drug Start dose Target Candesartan 4mg od 32mg od Losartan 25mg od 100mg od BETA- BLOCKER Bispoprolol Titration Carvedilol Titration Week 1 1.25mg od Week 2 2.5mg od Week 3 3.75mg od Week 4 5mg od Week 8 7.5mg od Week 12 10mg od Week 1 3.125mg bd Week 3 6.25mg bd Week 5 12.5 mg bd Week 7 25mg bd Week 9 *50mg bd *if weight >85kg

APPENDIX 3 - HEART FAILURE INTEGRATED CARE PATHWAY Diagnosis of chronic heart failure due to left ventricular systolic dysfunction (LVSD) Heart Failure Liaison Service aims: Develop a heart failure register. Refer to primary care for inclusion on heart failure and palliative care register. Carry out full assessments and assign treatment pathway based on patient s risk of decompensation. Introduce core issues relating to lifestyle changes, education, self management, carer support, and benefits advice. Review medication and plan optimised pharmacological management. Have access to and will refer to other health care professionals. The Heart Failure Liaison Service is based at: Address: Administration Building, Cameron Hospital, Windygates. Tel No: 01592-226884 Fax: 01592-226989 Email: Fife-uhb.heartfailureservice@ nhs.net The Specialist Nurses are available for support and advice and can be contacted by patients, their GPs and carers. Low Risk : Stable, established on treatment. Concordant with medication. Knowledgeable about condition. Adopting lifestyle changes and self managing. Receiving adequate social support. Annual Review within practice. Self management plan. Moderate Risk: Stable, requiring dose titration. Not fully concordant with medications. Minimal understanding of condition and impact of not modifying behaviour. Requiring support, education and structured case management. Frequent review. Anticipatory care plan. High Risk: Unstable, poor renal function. Symptomatic. Other co-morbidities, complex case management required. Poor understanding of condition and not concordant with medication. Requiring close monitoring of clinical status. Inadequate social support or haphazard followup. Advanced care plan. Community Nurse: Address and support lifestyle issues, education and self management. Access to HF Liaison service as required. Nurse with Specialist Knowledge: Address and provide further education on lifestyle issues, carer support, relaxation and anxiety management. Monitor dose titration. Intensive support for self management. Re-assessment/access to HF Liaison Service as required. Review as required. Heart Failure Specialist Service: Case management plan. Review by cardiology (when required). Increased level of social support and carer education. Symptom control, patient autonomy and choice, access to specialist palliative care as required. Managed as per Gold Standard Framework and inform GP of process and progress.